Mogamulizumab, an anti-CCR4 antibody, and brentuximab vedotin, a conjugated antibody against CD30, are FDA-approved for cutaneous T-cell lymphomas and showed good efficacy in previous studies [53,54]. This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.